Comparison · NCT03055013-deaths
Arm A (Nephrectomy + Nivolumab) vs Arm B (Nephrectomy Only): deaths from any cause
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Arm A (Nephrectomy + Nivolumab) vs Arm B (Nephrectomy Only): deaths from any cause. Trial comparisons, record NCT03055013-deaths. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT03055013-deaths
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.119 | 0.0908 | 0.154 | wilson | |
| Risk in group 2 | 0.0964 | 0.0716 | 0.129 | wilson | |
| Risk difference, group 1 minus group 2 | 0.0224 | -0.0203 | 0.0655 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.23 | 0.829 | 1.83 | log | |
| Odds ratio, group 1 over group 2 | 1.26 | 0.811 | 1.97 | log | |
| Number needed to harm, for one more death from any cause on Arm A (Nephrectomy + Nivolumab) than on Arm B (Nephrectomy Only) | 44.6 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Arm A (Nephrectomy + Nivolumab) | Patients receive nivolumab IV over 30 minutes on day 1. Treatment repeats every 14 days for 2 cycles. Patients then undergo partial or radical nephrectomy 7-28 days later. Patients then receive nivolumab over 30 IV on day 1. Treatment repeats every 14 days for 6 cycles, and then every 28 days for 6 cycles in the absence of disease progression or unacceptable toxicity.~Patients enrolled after Amendment 4 receive nivolumab IV over 30 minutes on day 1. Patients then undergo partial or radical nephrectomy 7-28 days later. Patient then receive nivolumab IV over 30 minutes on day 1. Treatment repeats every 4 weeks for up to 9 cycles in the absence of disease progression or unacceptable toxicity. | 48 | 404 | EG000 |
| Group 2 | Arm B (Nephrectomy Only) | Patients undergo partial or radical nephrectomy within 8 weeks after registration followed by observation. | 40 | 415 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, all-cause mortality
- Time frame
- Assessed every 4 weeks while on treatment and for 30 days after the end of treatment, up to 6 years
Source ClinicalTrials.gov
Trial
- Title
- Nivolumab in Treating Patients With Localized Kidney Cancer Undergoing Nephrectomy
- NCT number
- NCT03055013
- Phases
- PHASE3
- Conditions
- Metastatic Renal Cell Carcinoma, Sarcomatoid Renal Cell Carcinoma, Stage II Renal Cell Cancer AJCC v7, Stage III Renal Cell Cancer AJCC v7, Unclassified Renal Cell Carcinoma
- Interventions
- Nephrectomy, Nivolumab, Patient Observation, Quality-of-Life Assessment, Questionnaire Administration
- Lead sponsor
- National Cancer Institute (NCI)
- Results first posted
- 2024-04-25
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT03055013?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT03055013-deaths